 I. To evaluate atorvastatin induced modulation of breast cancer biomarkers markers EGFR, P-EGFR, ER, p21, p27, bcl-2, CC3, cytology and drug related markers LXR, total cholesterol, LDL, HDL, CRP in women who are at high risk to develop breast cancer. 